Exchange: NASDAQ·Updated 05:14 PM EDT

AUPH News

News
all
press releases
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock
Revealing a significant insider sell on August 26, Stephen P Robertson, Chief Legal Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), as per the latest SEC filing. What Happened: A Form 4 filing with the U.S. Securitiesread more...
Benzinga
More News
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Zacks
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.read more...
Benzinga
AUPH Stock Rallies 6% After-Hours — Here’s Why
Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.
Stocktwits
Aurinia Settles Patent Litigation with Teva
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, Aurinia) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (Teva) to resolve patent infringement litigation relating to Tevas filing of an...
Business Wire
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and...
Business Wire
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150...
Business Wire

Advertisement|Remove ads.